Search research articles
Contact Us
Filters
Showing results (731-740 of 967) with videos related to
Page
of 97
Sort By:
Journal for Immunotherapy of Cancer
|
May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
European Journal of Immunology
|
September 1, 1995
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21
S I Abrams, M J Dobrzanski, D T Wells, et al.
Medycyna Wieku Rozwojowego
|
October 20, 2009
[Detection of rare mutations in the dystrophin gene]
Janusz G Zimowski, Mariola Holding, Elzbieta Fidziańska, et al.
Neurologia I Neurochirurgia Polska
|
March 29, 2018
Evidence for a relatively high proportion of DM2 mutations in a large group of Polish patients
Anna Sulek, Anna Lusakowska, Wioletta Krysa, et al.
Nature Biotechnology
|
April 16, 2013
Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells
Fadi J Najm, Angela M Lager, Anita Zaremba, et al.
Nature
|
May 7, 2015
Complex archaea that bridge the gap between prokaryotes and eukaryotes
Anja Spang, Jimmy H Saw, Steffen L Jørgensen, et al.
Neurologia I Neurochirurgia Polska
|
June 9, 2018
WITHDRAWN: Evidence for a relatively high proportion of DM2 mutations in a large group of Polish patients
Anna Sulek, Anna Lusakowska, Wioletta Krysa, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
December 26, 2008
Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging
Laura-Adela Harsan, Jérôme Steibel, Anita Zaremba, et al.
Nature Neuroscience
|
September 5, 2017
Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion
Jeffrey D Zaremba, Anastasia Diamantopoulou, Nathan B Danielson, et al.
Pharmacoeconomics
|
July 7, 2021
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
Karen M Facey, Jaime Espin, Emma Kent, et al.
Page
of 97
Search research articles
Search
Showing results (731-740 of 967) with videos related to
Sort By:
Page
of 97
Journal for Immunotherapy of Cancer
|
May 31, 2019
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, et al.
European Journal of Immunology
|
September 1, 1995
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21
S I Abrams, M J Dobrzanski, D T Wells, et al.
Medycyna Wieku Rozwojowego
|
October 20, 2009
[Detection of rare mutations in the dystrophin gene]
Janusz G Zimowski, Mariola Holding, Elzbieta Fidziańska, et al.
Neurologia I Neurochirurgia Polska
|
March 29, 2018
Evidence for a relatively high proportion of DM2 mutations in a large group of Polish patients
Anna Sulek, Anna Lusakowska, Wioletta Krysa, et al.
Nature Biotechnology
|
April 16, 2013
Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells
Fadi J Najm, Angela M Lager, Anita Zaremba, et al.
Nature
|
May 7, 2015
Complex archaea that bridge the gap between prokaryotes and eukaryotes
Anja Spang, Jimmy H Saw, Steffen L Jørgensen, et al.
Neurologia I Neurochirurgia Polska
|
June 9, 2018
WITHDRAWN: Evidence for a relatively high proportion of DM2 mutations in a large group of Polish patients
Anna Sulek, Anna Lusakowska, Wioletta Krysa, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
December 26, 2008
Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging
Laura-Adela Harsan, Jérôme Steibel, Anita Zaremba, et al.
Nature Neuroscience
|
September 5, 2017
Impaired hippocampal place cell dynamics in a mouse model of the 22q11.2 deletion
Jeffrey D Zaremba, Anastasia Diamantopoulou, Nathan B Danielson, et al.
Pharmacoeconomics
|
July 7, 2021
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
Karen M Facey, Jaime Espin, Emma Kent, et al.
Page
of 97